Land: Canada
Sprog: engelsk
Kilde: Health Canada
FLUOXETINE (FLUOXETINE HYDROCHLORIDE)
MINT PHARMACEUTICALS INC
N06AB03
FLUOXETINE
10MG
CAPSULE
FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 10MG
ORAL
100
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0116847003; AHFS:
APPROVED
2012-02-24
_MINT-FLUOXETINE (Fluoxetine Capsules USP) _ _ _ _Page 1 of 55 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MINT-FLUOXETINE Fluoxetine Capsules USP Capsules, 10 mg and 20 mg fluoxetine (as fluoxetine hydrochloride), Oral Antidepressant / Antiobsessional / Antibulimic MINT Pharmaceuticals Inc. 6575 Davand Drive Mississauga, Ontario, L5T 2M3 Date of Initial Authorization: February 24, 2012 Date of Revision: February 21, 2022 Submission Control Number: 256561 _MINT-FLUOXETINE (Fluoxetine Capsules USP) _ _ _ _Page 2 of 55 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 02/2022 7 Warnings and Precautions, 7.1.1 Pregnant Women 02/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 5 4 DOSAGE AND ADMINISTRATION ...................................................................................... 6 4.1 Dosing Considerations ............................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment............................................................. 6 4.4 Administration.................... Læs hele dokumentet